How effective is Lamictal for Attention Deficit Hyperactivity Disorder? (a real world drug study)
Summary:
Overall ratings: 2.8/5 Long term ratings: 2.3/5
This is a phase IV clinical study of how effective Lamictal (lamotrigine) is for Attention deficit hyperactivity disorder and for what kind of people. The study is created by eHealthMe from 15 Lamictal users and is updated continuously.
What is Lamictal?
Lamictal has active ingredients of lamotrigine. It is often used in bipolar disorder. eHealthMe is studying from 82,626 Lamictal users. Check the latest studies of Lamictal.
What is Attention deficit hyperactivity disorder?
Attention deficit hyperactivity disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness) is found to be associated with 610 drugs and 1,393 conditions by eHealthMe. Check the latest studies of Attention deficit hyperactivity disorder.
15 people are studied for taking Lamictal in Attention deficit hyperactivity disorder
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Lamictal effectiveness for Attention deficit hyperactivity disorder (number of people):
Overall:
- not at all: 3
- somewhat: 3
- moderate: 5
- high: 2
- very high: 2
Long Term:
- not at all: 2
- somewhat: 2
- moderate: 1
- high: 0
- very high: 1
Gender of people who take Lamictal for Attention deficit hyperactivity disorder *:
- female: 66.67 %
- male: 33.33 %
Age of people who take Lamictal for Attention deficit hyperactivity disorder *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 6.67 %
- 20-29: 33.33 %
- 30-39: 13.33 %
- 40-49: 13.33 %
- 50-59: 33.33 %
- 60+: 0.0 %
Who find Lamictal more effective for Attention Deficit Hyperactivity Disorder?
Gender of people who take Lamictal for Attention deficit hyperactivity disorder *:
- female: 50 %
- male: 50 %
Age of people who take Lamictal for Attention deficit hyperactivity disorder *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 50 %
- 30-39: 0.0 %
- 40-49: 25 %
- 50-59: 25 %
- 60+: 0.0 %
* Approximation only. Some reports may have incomplete information.
Do you take Lamictal?
- You can start a phase IV clinical trial to monitor Lamictal safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies:
- Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
- Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
- Coskun M, Adak I, "Excessive and frequent menstrual bleeding with methylphenidate in an adolescent girl with attention-deficit hyperactivity disorder", Journal of clinical psychopharmacology, 2017 Oct .
- Lufi D, Bucherman M, Akita M, Cohen R, Sibani C, "The effect of methylphenidate on speech patterns of children with attention deficit disorder", Journal of Behavioral Health, 2012 Jan .
Related studies
Alternative drugs to, pros and cons of:
- Lamictal (82,626 reports)
Treatments, associated drugs and conditions:
- Attention deficit hyperactivity disorder (120,336 reports)
How the study uses the data?
The study is based on lamotrigine (the active ingredients of Lamictal) and Lamictal (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Septra Ds cause Hair Loss? - 3 seconds ago
- Drug interactions of Cellcept and Protonix - 10 seconds ago
- Drug interactions of Nplate and Protonix - 11 seconds ago
- Drug interactions of Abilify and Clozaril - 12 seconds ago
- Drug interactions of Sandimmune and Sucralfate - 16 seconds ago
- Could Tylenol cause Cervical Dysplasia? - 23 seconds ago
- Could Guaifenesin cause Renal Disorder? - 27 seconds ago
- Could Accutane cause Ear Barotrauma? - 27 seconds ago
- Could Venclexta cause Skin Burning Sensation? - 29 seconds ago
- Jaw Fracture and Malaise - 31 seconds ago